Topical Henna Preparation for the Treatment of Hand Foot Skin Syndrome
Primary Purpose
Hand Foot Skin Syndrome
Status
Withdrawn
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
henna paste
Sponsored by

About this trial
This is an interventional treatment trial for Hand Foot Skin Syndrome focused on measuring hand foot skin syndrome, palmar plantar erythrodysesthesia, doxorubicin, capecitabine
Eligibility Criteria
Inclusion Criteria:
- Patients receiving capecitabine and/or pegylated liposomal doxorubicin as monotherapy or in combination with other agents
- New diagnosis of active hand-foot skin reaction (on bilateral hands and/or bilateral feet) of 1-3 toxicity as defined by the NCI-CTCAE version 4.0 grading scale with onset of symptoms within the last thirty days
- Patients must be 18 years or older
- Patients must provide written informed consent to participate in the study
Exclusion Criteria:
- Patients with pre-existing dermatological condition affecting the hands or feet that may limit the interpretation of results
- Known allergy to natural henna
- Patients with a previous history of HFS
- History of G6PD deficiency as determined by screening bloodwork
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Other
Arm Label
Right
Left
Arm Description
Application of henna paste to right hand/foot plus CeraVe moisturizer
Application of henna paste to the left hand/foot plus CeraVe moisturizer
Outcomes
Primary Outcome Measures
• To compare the severity of HFS in subjects receiving topical natural henna paste treatment along with using CeraVe™ moisturizing cream concurrently on the treatment side and using only CeraVe™ moisturizing cream on the control side.
Secondary Outcome Measures
To examine quality of life, comparing natural henna treatment versus CeraVe™ alone, using the Skindex-16 questionnaire
Full Information
NCT ID
NCT01097850
First Posted
March 31, 2010
Last Updated
December 11, 2014
Sponsor
Northwestern University
1. Study Identification
Unique Protocol Identification Number
NCT01097850
Brief Title
Topical Henna Preparation for the Treatment of Hand Foot Skin Syndrome
Official Title
Prospective Randomized Controlled Open-label Trial of a Topical Henna Preparation for the Treatment of Hand-Foot Skin Syndrome and Its Associated Symptoms
Study Type
Interventional
2. Study Status
Record Verification Date
December 2014
Overall Recruitment Status
Withdrawn
Why Stopped
No subject accrual.
Study Start Date
March 2010 (undefined)
Primary Completion Date
January 2012 (Actual)
Study Completion Date
January 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Northwestern University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to determine whether henna paste is effective in the treatment of hand-foot skin syndrome, induced by the drugs Capecitabine and pegylated liposomal doxorubicin.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hand Foot Skin Syndrome
Keywords
hand foot skin syndrome, palmar plantar erythrodysesthesia, doxorubicin, capecitabine
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Right
Arm Type
Other
Arm Description
Application of henna paste to right hand/foot plus CeraVe moisturizer
Arm Title
Left
Arm Type
Other
Arm Description
Application of henna paste to the left hand/foot plus CeraVe moisturizer
Intervention Type
Drug
Intervention Name(s)
henna paste
Intervention Description
Henna paste will be applied to either the left hand/foot or right hand/foot, along with CeraVe moisturizer to both hands/feet
Primary Outcome Measure Information:
Title
• To compare the severity of HFS in subjects receiving topical natural henna paste treatment along with using CeraVe™ moisturizing cream concurrently on the treatment side and using only CeraVe™ moisturizing cream on the control side.
Time Frame
3 weeks
Secondary Outcome Measure Information:
Title
To examine quality of life, comparing natural henna treatment versus CeraVe™ alone, using the Skindex-16 questionnaire
Time Frame
3 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients receiving capecitabine and/or pegylated liposomal doxorubicin as monotherapy or in combination with other agents
New diagnosis of active hand-foot skin reaction (on bilateral hands and/or bilateral feet) of 1-3 toxicity as defined by the NCI-CTCAE version 4.0 grading scale with onset of symptoms within the last thirty days
Patients must be 18 years or older
Patients must provide written informed consent to participate in the study
Exclusion Criteria:
Patients with pre-existing dermatological condition affecting the hands or feet that may limit the interpretation of results
Known allergy to natural henna
Patients with a previous history of HFS
History of G6PD deficiency as determined by screening bloodwork
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Peter Lio, MD
Organizational Affiliation
Northwestern University
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Topical Henna Preparation for the Treatment of Hand Foot Skin Syndrome
We'll reach out to this number within 24 hrs